Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price hoisted by stock analysts at Barclays from $60.00 to $62.00 in a research note issued to investors on Tuesday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Barclays’ price target would suggest a potential upside of 19.78% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Canaccord Genuity reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 12th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $85.00 price target (down previously from $95.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, August 23rd. J P Morgan Chase & Co set a $76.00 price target on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a report on Wednesday, August 23rd. Robert W. Baird reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 19th. Finally, Cowen reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 15th. Ten investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $72.40.

Shares of Ultragenyx Pharmaceutical (RARE) traded up $0.06 during midday trading on Tuesday, reaching $51.76. 979,500 shares of the company traded hands, compared to its average volume of 434,677. Ultragenyx Pharmaceutical has a twelve month low of $44.02 and a twelve month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.87). The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.02 million. During the same period in the previous year, the business posted ($1.64) EPS. Ultragenyx Pharmaceutical’s revenue was up 81.8% compared to the same quarter last year. equities analysts expect that Ultragenyx Pharmaceutical will post -7.26 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Mercantile Trust Co. grew its position in shares of Ultragenyx Pharmaceutical by 1.7% during the 3rd quarter. First Mercantile Trust Co. now owns 2,339 shares of the biopharmaceutical company’s stock valued at $166,000 after purchasing an additional 39 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 3.7% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 115 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 9.4% during the 3rd quarter. Pacer Advisors Inc. now owns 2,237 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 192 shares during the last quarter. Prudential Financial Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 5.8% during the 1st quarter. Prudential Financial Inc. now owns 3,660 shares of the biopharmaceutical company’s stock worth $248,000 after acquiring an additional 200 shares during the last quarter. Finally, Amalgamated Bank lifted its holdings in shares of Ultragenyx Pharmaceutical by 4.6% during the 1st quarter. Amalgamated Bank now owns 4,628 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 202 shares during the last quarter. Hedge funds and other institutional investors own 94.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Ultragenyx Pharmaceutical (RARE) Price Target Raised to $62.00 at Barclays” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/05/ultragenyx-pharmaceutical-rare-price-target-raised-to-62-00-at-barclays.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.